Retention but significant reduction of BCR-ABL transcript in hematopoietic stem cells in chronic myelogenous leukemia after imatinib therapy

Chronic myelogenous leukemia (CML) is effectively treated with imatinib mesylate (IM), a small molecule inhibitor of the BCR-ABL tyrosine kinase that is expressed in the entire hematopoietic compartment including stem cells (HSC) and progenitors in CML patients. While IM induces disease remission, i...

Full description

Saved in:
Bibliographic Details
Main Authors: Abe, Akihiro, Minami, Yosuke, Hayakawa, Fumihiko, Kitamura, Kunio, Nomura, Yuka, Murata, Makoto, Katsumi, Akira, Kiyoi, Hitoshi, Jamieson, Catriona H. M., Wang, Jean Y. J., Naoe, Tomoki
Format: Artigo
Language:Inglês
Published: 2008
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC2626150/
https://ncbi.nlm.nih.gov/pubmed/19039626
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12185-008-0221-1
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items